CD10⁺ cell population in the bone marrow of patients with advanced neuroblastoma

Abstract

Immunocytologic analyses of bone marrow can provide clinically useful prognostic information in neuroblastoma. While analyzing the bone marrow with a panel of monoclonal antibodies, which detect neuroblasts and other defining B-, T-, and myloid lineage, we identified two infants with stage IV-S neuroblastoma whose bone marrow contained a large population of common acute lymphoblastic leukemia (ALL)-like cells. This population expressed HLA-DR, CD19(B1), CD10(CALLA), and occasionally CD20(B1). Since 1988, 17 additional patients with advanced neuroblastoma (IV-S, III, and IV) were studied by us. In 10 of the 19 patients, the bone marrow revealed an expanded CD10 population (20-70%). It appears that this group of patients has a better prognosis. Out of 9 patients who did not have an expanded CD10 population, 8 died within 9 months from diagnosis, whereas out of 10 patients with an expanded CD10 population only one died and the others are alive, 6-30 months from diagnosis (P < 0.001). An expanded CD10 population in the bone marrow of disseminated neuroblastoma patients may therefore serve as a prognostic factor. Apart from the prognostic value of this particular population in the single patient, its presence may shed light on the interrelationship between the immune system and the neuroendocrine compartment.

Detection of unidentified chromosome abnormalities in human neuroblastoma by spectral karyotyping (SKY)

“…However, the presence of single copies of MYCN, a normal 1p, near-triploidy, the presence of an expanded CD10 ϩ cell population in the bone marrow (Mandel et al, 1994), absence of an angiogenic phenotype, and the expression of the TRK gene (Nakagawara et al, 1993) are associated with a favorable prognosis.…”

Fuzzy Neural Network Applied to Gene Expression Profiling for Predicting the Prognosis of Diffuse Large B‐cell Lymphoma

“…Its expression has also been reported to be associated with a better response to treatment of acute lymphoblastic leukemia (ALL) and neuroblastoma. 20,21) CD10 is expressed in normal precursor B-cells and follicle center cells. 22,23) Leukemias and lymphomas originating from those cells, such as ALL and follicular lymphoma, also express CD10.…”